Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Impilo is advancing its Tumor-Penetrating Nanocomplex platform, to provide a targeted delivery approach for a wide range of nucleic acid treatment modalities including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) for solid tumor. ca...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Cend Therapeutics Announces Acquisition of Impilo Therapeutics
Details : CendR Platform combines Cend’s clinical-stage targeted tumor penetrating peptide, CEND-1. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of nucleic acid-based medicines t...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition